This company has been marked as potentially delisted and may not be actively trading.

GENFIT (GNFT) Competitors

GNFT vs. ORIC, EVMN, MRVI, SDGR, and SLS

Should you be buying GENFIT stock or one of its competitors? The main competitors of GENFIT include Oric Pharmaceuticals (ORIC), Evommune (EVMN), Maravai LifeSciences (MRVI), Schrodinger (SDGR), and SELLAS Life Sciences Group (SLS). These companies are all part of the "pharmaceutical products" industry.

How does GENFIT compare to Oric Pharmaceuticals?

GENFIT (NASDAQ:GNFT) and Oric Pharmaceuticals (NASDAQ:ORIC) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, risk, analyst recommendations, media sentiment, profitability, valuation and dividends.

: In the previous week, Oric Pharmaceuticals had 9 more articles in the media than GENFIT. MarketBeat recorded 9 mentions for Oric Pharmaceuticals and 0 mentions for GENFIT. GENFIT's average media sentiment score of 0.75 beat Oric Pharmaceuticals' score of -0.24 indicating that GENFIT is being referred to more favorably in the media.
Company Overall Sentiment
GENFIT Positive
Oric Pharmaceuticals Neutral
: GENFIT has a beta of 1.09, suggesting that its share price is 9% more volatile than the S&P 500. Comparatively, Oric Pharmaceuticals has a beta of 1.11, suggesting that its share price is 11% more volatile than the S&P 500.
: GENFIT has higher revenue and earnings than Oric Pharmaceuticals.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
GENFIT $41.52M 5.84 $1.63M N/A N/A
Oric Pharmaceuticals N/A N/A -$129.47M -$1.44 N/A
: 2.2% of GENFIT shares are held by institutional investors. Comparatively, 95.1% of Oric Pharmaceuticals shares are held by institutional investors. 4.2% of GENFIT shares are held by insiders. Comparatively, 5.6% of Oric Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
: GENFIT currently has a consensus target price of $7.00, indicating a potential upside of 44.33%. Oric Pharmaceuticals has a consensus target price of $19.80, indicating a potential upside of 106.90%. Given Oric Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Oric Pharmaceuticals is more favorable than GENFIT.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
GENFIT
1 Sell rating(s)
0 Hold rating(s)

1 Buy rating(s)

0 Strong Buy rating(s)
2.00
Oric Pharmaceuticals
1 Sell rating(s)

2 Hold rating(s)

11 Buy rating(s)

0 Strong Buy rating(s)
2.71
: GENFIT's return on equity of 0.00% beat Oric Pharmaceuticals' return on equity.
Company Net Margins Return on Equity Return on Assets
GENFIT N/A N/A N/A
Oric Pharmaceuticals N/A -36.37% -34.17%

Company	Overall Sentiment
GENFIT	Positive
Oric Pharmaceuticals	Neutral

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
GENFIT	$41.52M	5.84	$1.63M	N/A	N/A
Oric Pharmaceuticals	N/A	N/A	-$129.47M	-$1.44	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
GENFIT	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Oric Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.71

Company	Net Margins	Return on Equity	Return on Assets
GENFIT	N/A	N/A	N/A
Oric Pharmaceuticals	N/A	-36.37%	-34.17%

Summary

Oric Pharmaceuticals beats GENFIT on 7 of the 12 factors compared between the two stocks.

How does GENFIT compare to Evommune?

GENFIT (NASDAQ:GNFT) and Evommune (NYSE:EVMN) are both small-cap pharmaceutical products companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, valuation, media sentiment, analyst recommendations, profitability, dividends, institutional ownership and risk.

: GENFIT has higher revenue and earnings than Evommune.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
GENFIT $41.52M 5.84 $1.63M N/A N/A
Evommune $13M 66.98 -$68.87M -$8.07 N/A
: GENFIT currently has a consensus price target of $7.00, suggesting a potential upside of 44.33%. Evommune has a consensus price target of $49.13, suggesting a potential upside of 103.21%. Given Evommune's stronger consensus rating and higher probable upside, analysts plainly believe Evommune is more favorable than GENFIT.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
GENFIT
1 Sell rating(s)
0 Hold rating(s)

1 Buy rating(s)

0 Strong Buy rating(s)
2.00
Evommune
1 Sell rating(s)

1 Hold rating(s)

9 Buy rating(s)

3 Strong Buy rating(s)
3.00
: Company Net Margins Return on Equity Return on Assets
GENFIT N/A N/A N/A
Evommune N/A N/A N/A
: In the previous week, Evommune had 6 more articles in the media than GENFIT. MarketBeat recorded 6 mentions for Evommune and 0 mentions for GENFIT. GENFIT's average media sentiment score of 0.75 beat Evommune's score of 0.61 indicating that GENFIT is being referred to more favorably in the media.
Company Overall Sentiment
GENFIT Positive
Evommune Positive
: 2.2% of GENFIT shares are held by institutional investors. 4.2% of GENFIT shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
GENFIT	$41.52M	5.84	$1.63M	N/A	N/A
Evommune	$13M	66.98	-$68.87M	-$8.07	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
GENFIT	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Evommune	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	3 Strong Buy rating(s)	3.00

Company	Net Margins	Return on Equity	Return on Assets
GENFIT	N/A	N/A	N/A
Evommune	N/A	N/A	N/A

Company	Overall Sentiment
GENFIT	Positive
Evommune	Positive

Summary

Evommune beats GENFIT on 6 of the 11 factors compared between the two stocks.

How does GENFIT compare to Maravai LifeSciences?

GENFIT (NASDAQ:GNFT) and Maravai LifeSciences (NASDAQ:MRVI) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their earnings, media sentiment, analyst recommendations, profitability, risk, valuation, institutional ownership and dividends.

: In the previous week, Maravai LifeSciences had 6 more articles in the media than GENFIT. MarketBeat recorded 6 mentions for Maravai LifeSciences and 0 mentions for GENFIT. GENFIT's average media sentiment score of 0.75 beat Maravai LifeSciences' score of 0.57 indicating that GENFIT is being referred to more favorably in the media.
Company Overall Sentiment
GENFIT Positive
Maravai LifeSciences Positive
: GENFIT has a net margin of 0.00% compared to Maravai LifeSciences' net margin of -70.40%. GENFIT's return on equity of 0.00% beat Maravai LifeSciences' return on equity.
Company Net Margins Return on Equity Return on Assets
GENFIT N/A N/A N/A
Maravai LifeSciences -70.40% -22.79% -11.82%
: GENFIT currently has a consensus price target of $7.00, suggesting a potential upside of 44.33%. Maravai LifeSciences has a consensus price target of $5.38, suggesting a potential upside of 39.61%. Given GENFIT's higher possible upside, equities research analysts clearly believe GENFIT is more favorable than Maravai LifeSciences.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
GENFIT
1 Sell rating(s)
0 Hold rating(s)

1 Buy rating(s)

0 Strong Buy rating(s)
2.00
Maravai LifeSciences
1 Sell rating(s)

1 Hold rating(s)

3 Buy rating(s)

0 Strong Buy rating(s)
2.40
: GENFIT has higher earnings, but lower revenue than Maravai LifeSciences.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
GENFIT $41.52M 5.84 $1.63M N/A N/A
Maravai LifeSciences $185.74M 5.33 -$130.77M -$0.90 N/A
: GENFIT has a beta of 1.09, suggesting that its share price is 9% more volatile than the S&P 500. Comparatively, Maravai LifeSciences has a beta of 0.62, suggesting that its share price is 38% less volatile than the S&P 500.
: 2.2% of GENFIT shares are owned by institutional investors. Comparatively, 50.3% of Maravai LifeSciences shares are owned by institutional investors. 4.2% of GENFIT shares are owned by insiders. Comparatively, 2.5% of Maravai LifeSciences shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Company	Overall Sentiment
GENFIT	Positive
Maravai LifeSciences	Positive

Company	Net Margins	Return on Equity	Return on Assets
GENFIT	N/A	N/A	N/A
Maravai LifeSciences	-70.40%	-22.79%	-11.82%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
GENFIT	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Maravai LifeSciences	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
GENFIT	$41.52M	5.84	$1.63M	N/A	N/A
Maravai LifeSciences	$185.74M	5.33	-$130.77M	-$0.90	N/A

Summary

GENFIT beats Maravai LifeSciences on 9 of the 14 factors compared between the two stocks.

How does GENFIT compare to Schrodinger?

Schrodinger (NASDAQ:SDGR) and GENFIT (NASDAQ:GNFT) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, earnings, valuation, media sentiment, risk, analyst recommendations, profitability and institutional ownership.

: In the previous week, Schrodinger had 8 more articles in the media than GENFIT. MarketBeat recorded 8 mentions for Schrodinger and 0 mentions for GENFIT. GENFIT's average media sentiment score of 0.75 beat Schrodinger's score of -0.28 indicating that GENFIT is being referred to more favorably in the news media.
Company Overall Sentiment
Schrodinger Neutral
GENFIT Positive
: GENFIT has a net margin of 0.00% compared to Schrodinger's net margin of -40.37%. GENFIT's return on equity of 0.00% beat Schrodinger's return on equity.
Company Net Margins Return on Equity Return on Assets
Schrodinger -40.37% -29.47% -14.69%
GENFIT N/A N/A N/A
: Schrodinger presently has a consensus price target of $20.50, suggesting a potential upside of 59.29%. GENFIT has a consensus price target of $7.00, suggesting a potential upside of 44.33%. Given Schrodinger's stronger consensus rating and higher probable upside, analysts clearly believe Schrodinger is more favorable than GENFIT.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Schrodinger
1 Sell rating(s)
4 Hold rating(s)

4 Buy rating(s)

0 Strong Buy rating(s)
2.33
GENFIT
1 Sell rating(s)

0 Hold rating(s)

1 Buy rating(s)

0 Strong Buy rating(s)
2.00
: GENFIT has lower revenue, but higher earnings than Schrodinger.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Schrodinger $255.87M 3.71 -$103.26M -$1.42 N/A
GENFIT $41.52M 5.84 $1.63M N/A N/A
: Schrodinger has a beta of 1.57, suggesting that its stock price is 57% more volatile than the S&P 500. Comparatively, GENFIT has a beta of 1.09, suggesting that its stock price is 9% more volatile than the S&P 500.
: 79.1% of Schrodinger shares are owned by institutional investors. Comparatively, 2.2% of GENFIT shares are owned by institutional investors. 21.0% of Schrodinger shares are owned by company insiders. Comparatively, 4.2% of GENFIT shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Company	Overall Sentiment
Schrodinger	Neutral
GENFIT	Positive

Company	Net Margins	Return on Equity	Return on Assets
Schrodinger	-40.37%	-29.47%	-14.69%
GENFIT	N/A	N/A	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Schrodinger	1 Sell rating(s)	4 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.33
GENFIT	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Schrodinger	$255.87M	3.71	-$103.26M	-$1.42	N/A
GENFIT	$41.52M	5.84	$1.63M	N/A	N/A

Summary

Schrodinger beats GENFIT on 8 of the 14 factors compared between the two stocks.

How does GENFIT compare to SELLAS Life Sciences Group?

SELLAS Life Sciences Group (NASDAQ:SLS) and GENFIT (NASDAQ:GNFT) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, dividends, earnings, media sentiment, profitability, analyst recommendations, institutional ownership and valuation.

: 17.4% of SELLAS Life Sciences Group shares are owned by institutional investors. Comparatively, 2.2% of GENFIT shares are owned by institutional investors. 1.2% of SELLAS Life Sciences Group shares are owned by company insiders. Comparatively, 4.2% of GENFIT shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
: In the previous week, SELLAS Life Sciences Group had 3 more articles in the media than GENFIT. MarketBeat recorded 3 mentions for SELLAS Life Sciences Group and 0 mentions for GENFIT. GENFIT's average media sentiment score of 0.75 beat SELLAS Life Sciences Group's score of 0.54 indicating that GENFIT is being referred to more favorably in the news media.
Company Overall Sentiment
SELLAS Life Sciences Group Positive
GENFIT Positive
: GENFIT's return on equity of 0.00% beat SELLAS Life Sciences Group's return on equity.
Company Net Margins Return on Equity Return on Assets
SELLAS Life Sciences Group N/A -63.06% -54.50%
GENFIT N/A N/A N/A
: SELLAS Life Sciences Group has a beta of 2.24, suggesting that its stock price is 124% more volatile than the S&P 500. Comparatively, GENFIT has a beta of 1.09, suggesting that its stock price is 9% more volatile than the S&P 500.
: GENFIT has higher revenue and earnings than SELLAS Life Sciences Group.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
SELLAS Life Sciences Group N/A N/A -$26.86M -$0.25 N/A
GENFIT $41.52M 5.84 $1.63M N/A N/A
: SELLAS Life Sciences Group presently has a consensus price target of $10.00, suggesting a potential upside of 105.34%. GENFIT has a consensus price target of $7.00, suggesting a potential upside of 44.33%. Given SELLAS Life Sciences Group's higher probable upside, equities analysts plainly believe SELLAS Life Sciences Group is more favorable than GENFIT.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
SELLAS Life Sciences Group
1 Sell rating(s)
0 Hold rating(s)

1 Buy rating(s)

0 Strong Buy rating(s)
2.00
GENFIT
1 Sell rating(s)

0 Hold rating(s)

1 Buy rating(s)

0 Strong Buy rating(s)
2.00

Company	Overall Sentiment
SELLAS Life Sciences Group	Positive
GENFIT	Positive

Company	Net Margins	Return on Equity	Return on Assets
SELLAS Life Sciences Group	N/A	-63.06%	-54.50%
GENFIT	N/A	N/A	N/A

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
SELLAS Life Sciences Group	N/A	N/A	-$26.86M	-$0.25	N/A
GENFIT	$41.52M	5.84	$1.63M	N/A	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
SELLAS Life Sciences Group	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
GENFIT	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

GENFIT beats SELLAS Life Sciences Group on 6 of the 10 factors compared between the two stocks.

Get GENFIT News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding GNFT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

GNFT vs. The Competition

Export

Metric	GENFIT	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$242.62M	$3.40B	$6.25B	$11.76B
Dividend Yield	N/A	2.23%	2.74%	5.26%
P/E Ratio	N/A	38.57	29.24	27.07
Price / Sales	5.84	280.01	504.68	73.40
Price / Cash	69.34	125.06	43.30	53.90
Price / Book	3.23	7.05	9.67	6.69
Net Income	$1.63M	$23.62M	$3.55B	$332.64M

GENFIT Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
GNFT GENFIT	0.7952 of 5 stars	$4.85 flat	$7.00 +44.3%	N/A	$242.62M	$41.52M	N/A	120
ORIC Oric Pharmaceuticals	2.1384 of 5 stars	$9.65 -5.3%	$19.90 +106.2%	+67.9%	$968.47M	N/A	N/A	80	Earnings Report Analyst Forecast
EVMN Evommune	N/A	$25.60 +2.4%	$48.43 +89.2%	N/A	$922.17M	$13M	N/A	45	Lockup Expiration
MRVI Maravai LifeSciences	2.2913 of 5 stars	$3.56 -3.3%	$5.38 +51.0%	+81.6%	$915.17M	$185.74M	N/A	610	Upcoming Earnings
SDGR Schrodinger	2.7412 of 5 stars	$12.24 +4.3%	$20.50 +67.5%	-50.5%	$903.56M	$255.87M	N/A	790	News Coverage Earnings Report

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:GNFT) was last updated on 5/6/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

GENFIT (GNFT) Competitors

GNFT vs. ORIC, EVMN, MRVI, SDGR, and SLS

How does GENFIT compare to Oric Pharmaceuticals?

Summary

How does GENFIT compare to Evommune?

Summary

How does GENFIT compare to Maravai LifeSciences?

Summary

How does GENFIT compare to Schrodinger?

Summary

How does GENFIT compare to SELLAS Life Sciences Group?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GNFT vs. The Competition

GENFIT Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

GENFIT (GNFT) Competitors

GNFT vs. ORIC, EVMN, MRVI, SDGR, and SLS

How does GENFIT compare to Oric Pharmaceuticals?

Summary

How does GENFIT compare to Evommune?

Summary

How does GENFIT compare to Maravai LifeSciences?

Summary

How does GENFIT compare to Schrodinger?

Summary

How does GENFIT compare to SELLAS Life Sciences Group?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GNFT vs. The Competition

GENFIT Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools